{"organizations": [], "uuid": "64867aeb03fa43c5fbd8bc0346429eb5e4c6ae85", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180212.html", "section_title": "Archive News &amp; Video for Monday, 12 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-horizon-discovery-enters-into-an-a/brief-horizon-discovery-enters-into-an-agreement-with-a-immuno-oncology-therapeutics-developer-idUSFWN1Q20SL", "country": "US", "domain_rank": 408, "title": "BRIEF-Horizon Discovery Enters into An Agreement With A Immuno-Oncology Therapeutics Developer​", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.091, "site_type": "news", "published": "2018-02-12T20:18:00.000+02:00", "replies_count": 0, "uuid": "64867aeb03fa43c5fbd8bc0346429eb5e4c6ae85"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-horizon-discovery-enters-into-an-a/brief-horizon-discovery-enters-into-an-agreement-with-a-immuno-oncology-therapeutics-developer-idUSFWN1Q20SL", "ord_in_thread": 0, "title": "BRIEF-Horizon Discovery Enters into An Agreement With A Immuno-Oncology Therapeutics Developer​", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 12 (Reuters) - Horizon Discovery Group Plc:\n* HORIZON DISCOVERY GROUP PLC - ‍ENTERED INTO A NON-EXCLUSIVE OUT-LICENSING AGREEMENT WITH A US-BASED IMMUNO-ONCOLOGY THERAPEUTICS DEVELOPER​\n* HORIZON DISCOVERY -DEAL FOR CO‘S PROPRIETARY TECHNOLOGIES TO SUPPORT DEVELOPMENT,MANUFACTURE OF NOVEL BIOMANUFACTURING CELL LINE FOR COMMERCIAL USE​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-12T20:18:00.000+02:00", "crawled": "2018-02-13T15:33:59.005+02:00", "highlightTitle": ""}